TG Therapeutics (NASDAQ:TGTX) jumps 23% premarket on positive topline resultsfrom two global, Phase 3 studies, called ULTIMATE I & ULTIMATE II, evaluating ublituximab, an investigational, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS).
The ULTIMATE I & II trials enrolled a total of 1,094 patients. Both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial).
Ublituximab resulted in an ARR of <0.10 in each of ULTIMATE studies, with a relative reduction in ARR of ~60% and 50%, respectively, over teriflunomide.
Further analyses of both the studies including safety and secondary endpoints will be presented at an upcoming medical congress, targeted in H1 2021.
Additionally, data from these studies are intended to support a BLA submission for ublituximab in RMS targeted in mid-year 2021.
The company will host a conference call today at 8:30 AM ET to discuss the ULTIMATE I & II topline results.